# Merck Acquires Verona Pharma for $10 Billion

> ma · REPORTED · 2025-01-01

Merck acquired Verona Pharma for $10 billion to obtain Ohtuvayre (ensifentrine), an FDA-approved first-in-class dual PDE3/PDE4 inhibitor for COPD maintenance treatment, significantly expanding Merck's cardio-pulmonary pipeline.

- Company: Merck
- Sector: therapeutics
- Primary source: https://www.drugdiscoverytrends.com/2025-pharma-ma-surges-to-70-billion/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.